Literature DB >> 21397370

SPF32629A and SPF32629B: enantioselective synthesis, determination of absolute configuration, cytotoxicity and antibacterial evaluation.

Srinivasa Rao Vegi1, Shanthaveerappa K Boovanahalli, Balaram Patro, K Mukkanti.   

Abstract

We report herein an efficient enantioselective synthesis of SPF32629A and SPF32629B through one-pot enantioselective reduction and protecting-group-free regioselective O-acylation strategy. The absolute configuration of the enantiomerically pure isomers was established by Mosher ester analysis. The inhibitory potencies of the synthesized compounds were assayed in vitro against a panel of microorganisms and against A549 human lung adenocarcinoma cell line. Compounds 2, 11 and 12 displayed moderate to potent antibacterial activity against all the tested strains and compounds 7, 8, 2, 11 and 12 exhibited significant cytotoxicity in a dose-dependent manner with an IC50 values ranging from 2.92 to 4.14 μg/ml and 8-11 μM.
Copyright © 2011 Elsevier Masson SAS. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21397370     DOI: 10.1016/j.ejmech.2011.02.039

Source DB:  PubMed          Journal:  Eur J Med Chem        ISSN: 0223-5234            Impact factor:   6.514


  3 in total

1.  Dapson in heterocyclic chemistry, part VIII: synthesis, molecular docking and anticancer activity of some novel sulfonylbiscompounds carrying biologically active 1,3-dihydropyridine, chromene and chromenopyridine moieties.

Authors:  Mansour S Al-Said; Mostafa M Ghorab; Yassin M Nissan
Journal:  Chem Cent J       Date:  2012-07-02       Impact factor: 4.215

2.  Synthesis and biological evaluation of 2-oxonicotinonitriles and 2-oxonicotinonitrile based nucleoside analogues.

Authors:  Reham A I Abou-Elkhair; Ahmed H Moustafa; Abdelfattah Z Haikal; Ahmed M Ibraheem
Journal:  Eur J Med Chem       Date:  2014-01-08       Impact factor: 6.514

3.  Iterative synthesis of nitrogen-containing polyketide via oxime intermediates.

Authors:  Yuta Takeuchi; Shun Kawasaki; Kengo Akagawa; Kazuaki Kudo
Journal:  RSC Adv       Date:  2022-02-11       Impact factor: 3.361

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.